All doses/ schedules of Trudexa lon in all four studies showed statistically significantly greater improvement in the disability index of the HAQ from baseline to Month 6 compared to placebo and in Study III the same was seen at week 52.
indeksi statistiliselt oluliselt suuremat paranemist lähteväärtusest 6. kuuni ning uuringus III täheldati sama 52. nädalal.